Telix Pharmaceuticals (TLX) Stock Statistics & Valuation Metrics

Telix Pharmaceuticals has a market cap or net worth of $8.65B. The enterprise value is AU$8.51B.

Telix Pharmaceuticals has 338,248,780 shares outstanding. The number of shares has decreased by -2.65% in one year.

Telix Pharmaceuticals’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 6.06%.

The current PE Ratio of Telix Pharmaceuticals is 163.29. Telix Pharmaceuticals’s PEG ratio is 0.52.

In the last 12 months, Telix Pharmaceuticals had revenue of 783.21M and earned 49.92M in profits. Earnings per share was 0.15.

In the last 12 months, operating cash flow was 43.03M and capital expenditures -34.03M, giving a free cash flow of 9.00M billion.

Telix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Telix Pharmaceuticals upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.

Telix Pharmaceuticals as a current ratio of 2.78, with Debt / Equity ratio of 102.33%

In the past 12 months, Telix Pharmaceuticals has paid 6.14M in taxes.

Telix Pharmaceuticals EV to EBITDA ratio is 86.69, with an EV/FCF ratio of 891.69.

Telix Pharmaceuticals has $710.35M in cash and marketable securities with AU$581.45M in debt, giving a net cash position of -$128.90M billion.

Gross margin is 73.91%, with operating margin of 10.49%, and net profit margin of 6.37%.

The average price target for Telix Pharmaceuticals is $34.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy